An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

NCT03094429 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

287

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Schizophrenia

Interventions

DRUG: NaBen®
OTHER: Placebo

Sponsor

SyneuRx International (Taiwan) Corp

Collaborators

[object Object]